BiTEs and CAR-Ts : immunotherapy in childhood B-cell acute lymphoblastic leukemia

Thesis: S.M., Massachusetts Institute of Technology, Department of Biology, 2018. === Cataloged from PDF version of thesis. === Includes bibliographical references (pages 18-21). === B-cell acute lymphoblastic leukemia is the most common pediatric cancer, responsible for the most cancer-related deat...

Full description

Bibliographic Details
Main Author: Besada, Rana Hany
Other Authors: Michael T. Hemann.
Format: Others
Language:English
Published: Massachusetts Institute of Technology 2018
Subjects:
Online Access:http://hdl.handle.net/1721.1/115699
id ndltd-MIT-oai-dspace.mit.edu-1721.1-115699
record_format oai_dc
spelling ndltd-MIT-oai-dspace.mit.edu-1721.1-1156992019-05-02T16:37:08Z BiTEs and CAR-Ts : immunotherapy in childhood B-cell acute lymphoblastic leukemia Immunotherapy in childhood B-cell acute lymphoblastic leukemia Besada, Rana Hany Michael T. Hemann. Massachusetts Institute of Technology. Department of Biology. Massachusetts Institute of Technology. Department of Biology. Biology. Thesis: S.M., Massachusetts Institute of Technology, Department of Biology, 2018. Cataloged from PDF version of thesis. Includes bibliographical references (pages 18-21). B-cell acute lymphoblastic leukemia is the most common pediatric cancer, responsible for the most cancer-related deaths in children. Advances in chemotherapy over the past half-century have steadily increased the remission and survival of children with B-cell acute lymphoblastic leukemia to nearly 90%. However, the problems of minimal residual disease and relapsed and refractory disease persist. Personalized, targeted therapies have improved outcomes among the minority of patients for whom chemotherapy is ineffective. Immunotherapy, specifically bispecific T-cell engaging antibody therapy and chimeric antigen receptor T-cell therapy, has proven an effective treatment for relapsed and refractory B-cell acute lymphoblastic leukemia in children. These new modalities, however, have also introduced new adverse side effects to the treatment regimen. Though immunotherapy has increased remission and survival, more work must be done to reduce adverse effects and eliminate relapsed and refractory disease. by Rana Hany Besada. S.M. 2018-05-23T16:30:50Z 2018-05-23T16:30:50Z 2018 2018 Thesis http://hdl.handle.net/1721.1/115699 1036985876 eng MIT theses are protected by copyright. They may be viewed, downloaded, or printed from this source but further reproduction or distribution in any format is prohibited without written permission. http://dspace.mit.edu/handle/1721.1/7582 22 pages application/pdf Massachusetts Institute of Technology
collection NDLTD
language English
format Others
sources NDLTD
topic Biology.
spellingShingle Biology.
Besada, Rana Hany
BiTEs and CAR-Ts : immunotherapy in childhood B-cell acute lymphoblastic leukemia
description Thesis: S.M., Massachusetts Institute of Technology, Department of Biology, 2018. === Cataloged from PDF version of thesis. === Includes bibliographical references (pages 18-21). === B-cell acute lymphoblastic leukemia is the most common pediatric cancer, responsible for the most cancer-related deaths in children. Advances in chemotherapy over the past half-century have steadily increased the remission and survival of children with B-cell acute lymphoblastic leukemia to nearly 90%. However, the problems of minimal residual disease and relapsed and refractory disease persist. Personalized, targeted therapies have improved outcomes among the minority of patients for whom chemotherapy is ineffective. Immunotherapy, specifically bispecific T-cell engaging antibody therapy and chimeric antigen receptor T-cell therapy, has proven an effective treatment for relapsed and refractory B-cell acute lymphoblastic leukemia in children. These new modalities, however, have also introduced new adverse side effects to the treatment regimen. Though immunotherapy has increased remission and survival, more work must be done to reduce adverse effects and eliminate relapsed and refractory disease. === by Rana Hany Besada. === S.M.
author2 Michael T. Hemann.
author_facet Michael T. Hemann.
Besada, Rana Hany
author Besada, Rana Hany
author_sort Besada, Rana Hany
title BiTEs and CAR-Ts : immunotherapy in childhood B-cell acute lymphoblastic leukemia
title_short BiTEs and CAR-Ts : immunotherapy in childhood B-cell acute lymphoblastic leukemia
title_full BiTEs and CAR-Ts : immunotherapy in childhood B-cell acute lymphoblastic leukemia
title_fullStr BiTEs and CAR-Ts : immunotherapy in childhood B-cell acute lymphoblastic leukemia
title_full_unstemmed BiTEs and CAR-Ts : immunotherapy in childhood B-cell acute lymphoblastic leukemia
title_sort bites and car-ts : immunotherapy in childhood b-cell acute lymphoblastic leukemia
publisher Massachusetts Institute of Technology
publishDate 2018
url http://hdl.handle.net/1721.1/115699
work_keys_str_mv AT besadaranahany bitesandcartsimmunotherapyinchildhoodbcellacutelymphoblasticleukemia
AT besadaranahany immunotherapyinchildhoodbcellacutelymphoblasticleukemia
_version_ 1719043761517887488